Erlotinib prevents pulmonary metastasis in curatively resected breast carcinoma using a mouse model

Oncology Reports

Volumn 16, Issue 1, 2006, Pages 119-122

  Choi, Young Jin ^a   Nam, Seok Jin ^a   Son, Myung Jin ^a   Kim, Dae Kyeum ^a   Kim, Jeong Han ^a   Yang, Jung Hyun ^a   Kim, Mi Hyun ^a   Song, Hyun Seok ^a   Nam, Do Hyun ^a   Bang, Sa Ik ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Breast carcinoma; Epidermal growth factor receptor tyrosine kinase inhibitor; Erlotinib; Paclitaxel; Pulmonary metastasis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BREAST TUMOR; CANCER TRANSPLANTATION; DISEASE MODEL; FEMALE; HUMAN; LUNG TUMOR; METABOLISM; METASTASIS; MOUSE; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33750713070     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.16.1.119     Document Type: Article

References (17)

1. Gasparini G, Longo R, Torino F and Morabito A: Therapy of breast cancer with molecular targeting agents. Ann Oncol 16: iv28-iv36, 2005. (Pubitemid 43084943)
2. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL and Massague J: Genes that mediate breast cancer metastasis to lung. Nature 436: 518-524, 2005. (Pubitemid 41112921)
3. Solomayer EF, Diel IJ, Meyberg GC, Gollan C and Bastert G: Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 59: 271-278, 2000. (Pubitemid 30243049)
4. Krozely P: Epidermal growth factor receptor tyrosine kinase inhibitors: involving role in the treatment of solid tumors. Clin J Oncol Nurs 8: 163-168, 2004.
5. Pal SK and Pegram M: Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy. Anticancer Drugs 16: 483-494, 2005. (Pubitemid 40685732)
6. Moasser MM, Basso A, Averbuch SD and Rosen N: The tyrosine kinase inhibitor ZD1839 ('Iressa') inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61: 7184-7188, 2001. (Pubitemid 32946513)
7. Dieras V, Pierga JY, Vincent-Salomon A, Beuzeboc P, Pouillart P and de Cremoux P: Targeting epidermal growth factor receptor in cancer of the breast. Bull Cancer 90: S257-S262, 2003. (Pubitemid 37523806)
8. Tan AR, Yang X, Hewitt SM, Berman A, Lepper ER, Sparreboom A, Parr AL, Figg WD, Chow C, Steinberg SM, Bacharach SL, Whatley M, Carrasquillo JA, Brahim JS, Ettenberg SA, Lipkowitz S and Swain SM: Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol 22: 3080-3090, 2004. (Pubitemid 41103720)
9. Minna JD and Dowell J: Erlotinib hydrochloride. Nat Rev Drug Discov Suppl: S14-S15, 2005. (Pubitemid 40674339)
10. Price JE and Zhang RD: Studies of human breast cancer metastasis using nude mice. Cancer Metastasis Rev 8: 285-297, 1990.
11. Cohen MH, Johnson JR, Chen YF, Sridhara R and Pazdur R: FDA drug approval summary: erlotinib (tarceva®) tablets. Oncologist 10: 461-466, 2005. (Pubitemid 41266326)
12. Huether A, Hopfner M, Sutter AP, Schuppan D and Scherubl H: Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. J Hepatol 43: 661-669, 2005. (Pubitemid 41253234)
13. Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, Baumber R, Lamborn KR, Kapadia A, Malec M, Berger MS and Stokoe D: Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97: 880-887, 2005. (Pubitemid 41417939)
14. Lichtner RB: Estrogen/EGF receptor interactions in breast cancer: rationale for new therapeutic combination strategies. Biomed Pharmacother 57: 447-451, 2003.
15. Zhu BD, Yuan SJ, Zhao QC, Li X, Li Y and Lu QY: Antitumor effect of Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with cytotoxic agent on murine hepatocellular carcinoma. World J Gastroenterol 11: 1382-1386, 2005. (Pubitemid 40425926)
16. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A and Johnson DH: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 22: 785-794, 2004. (Pubitemid 41103589)
17. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF and Arteaga CL: Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61: 8887-8895, 2001. (Pubitemid 34013905)